Outcome of Annual General Meeting of April 27, 2015

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that during its Annual General Meeting (“AGM”) which took place on April 27, 2015, in Marseille, France: A number of 27,560,731 votes were expressed out of a total of 53,144,454 shares with voting rights, representing a quorum of 51.86%.
Details of the votes are available on the Company’s website, in the investors’ room (http://www.innate-pharma.com/AGMdocuments).

During the meeting, Véronique Chabernaud was appointed as a new member of the Supervisory Board.

"We are very pleased that Ms. Véronique Chabernaud joins the Supervisory Board of Innate Pharma. Her comprehensive career in the pharmaceutical industry and her extensive knowledge of public health issues will be an asset to the Company”, said Gilles Brisson, Chairman of the Supervisory Board of Innate Pharma. He added: “As we embark in a new stage of growth with the major partnership signed with AstraZeneca, Innate Pharma strengthens its governance with a new independent member, in the perspective of a sustainable development.”

Véronique Chabernaud, aged 53, oncologist and ESSEC graduate, occupied for 20 years both national and international top-ranked positions in the pharmaceutical industry notably at Sanofi-Aventis. She was also consultant with companies in the innovative technology sector (Genomic Health, BioSystems International, MaunaKea Technologies, Ariana Pharma). She is also interested by the development of a global health approach.

To date, the Supervisory Board of Innate Pharma is composed of:

• Gilles Brisson, Chairman, Independent member;
• Irina Staatz-Granzer, Vice-Chairman, Independent member;
• Novo Nordisk A/S, represented by Karsten Munk Knudsen, Non-independent member;
• Patrick Langlois, Non-independent member;
• Philippe Pouletty, Independent member;
• Michael Caligiuri, Independent member;
• Véronique Chabernaud, Independent member;
• BPI Groupe, represented by Olivier Martinez, Observer.

The 2014 Activity and Responsibility Report and the 2014 Reference Document of the Company are available on its website.